Episode Details

Moderna’s biggest mRNA test since COVID could change how cancer is treated. In this condensed recap of the a16z Podcast episode, host Horge Kai speaks with Moderna CEO Stéphane Bancel about the company’s positive phase 3 melanoma trial with Merck, where the personalized mRNA cancer vaccine outperformed Keytruda alone on recurrence-free and distant metastasis-free survival. Learn how Moderna uses tumor sequencing, mutation selection, and automated mRNA manufacturing to “teach” the immune system, why the treatment’s 42-day needle-to-needle timeline matters, and what the results could mean for melanoma, pancreatic cancer, gastric cancer, and other hard-to-treat diseases. Compared with the full episode, this summary gives you the key biotechnology, immunotherapy, and business insights in minutes rather than the full conversation. Listen now to get the key ideas in minutes.